Sex differences in global metabolomic profiles of COVID-19 patients.
Sex differences in global metabolomic profiles of COVID-19 patients.
复制标题
COVID-19患者总体代谢组学特征的性别差异。
DOI：
10.1038/s41419-022-04861-2
复制
发表时间：
2022-05-14
影响因子：
9
通讯作者：
Tsvetkov, Andrey S.
中科院分区：
文献类型：
--
作者：
Escarcega, Rocio Diaz;Honarpisheh, Pedram;Colpo, Gabriela Delevati;Ahnstedt, Hilda W.;Couture, Lucy;Juneja, Shivanki;Torres, Glenda;Ortiz, Guadalupe J.;Sollome, James;Tabor, Natalie;Ganesh, Bhanu P.;Choi, H. Alex;Liu, Fudong;McCullough, Louise D.;Tsvetkov, Andrey S.
由SARS-CoV-2引起的冠状病毒病（COVID-19）导致从无症状疾病到死亡的症状。尽管男性更容易出现COVID-19导致的严重症状和更高的死亡率，但很少检查患者性别。性别相关的代谢变化可能涉及新的生物标志物和治疗靶点，以治疗COVID-19。在这里，我们使用血清样本，对未感染和SARS-CoV-2阳性的严重COVID-19男性和女性患者进行了整体代谢组学分析。在COVID-19组中表现出强烈性别差异的关键代谢途径，但在对照组中没有，涉及脂质代谢、戊糖途径、胆汁酸代谢和芳香族氨基酸（包括色氨酸和酪氨酸）的微生物组相关代谢。无监督统计分析显示，患者特异性临床参数与其总体代谢特征之间的相关性存在深刻的性别二态性。对于致力于为COVID-19患者开发潜在的性别相关生物标志物和药物靶点的研究人员来说，确定严重COVID-19患者的性别特异性代谢变化是一个重要的知识来源。
Coronavirus disease (COVID-19), caused by SARS-CoV-2, leads to symptoms ranging from asymptomatic disease to death. Although males are more susceptible to severe symptoms and higher mortality due to COVID-19, patient sex has rarely been examined. Sex-associated metabolic changes may implicate novel biomarkers and therapeutic targets to treat COVID-19. Here, using serum samples, we performed global metabolomic analyses of uninfected and SARS-CoV-2-positive male and female patients with severe COVID-19. Key metabolic pathways that demonstrated robust sex differences in COVID-19 groups, but not in controls, involved lipid metabolism, pentose pathway, bile acid metabolism, and microbiome-related metabolism of aromatic amino acids, including tryptophan and tyrosine. Unsupervised statistical analysis showed a profound sexual dimorphism in correlations between patient-specific clinical parameters and their global metabolic profiles. Identification of sex-specific metabolic changes in severe COVID-19 patients is an important knowledge source for researchers striving for development of potential sex-associated biomarkers and druggable targets for COVID-19 patients.
登录
查看更多内容
影响因子：
8.9
作者：
Alkhouli, Mohamad;Nanjundappa, Aravinda;Bhatt, Deepak L.
通讯作者：
Bhatt, Deepak L.
影响因子：
3.7
作者：
Lau ES;McNeill JN;Paniagua SM;Liu EE;Wang JK;Bassett IV;Selvaggi CA;Lubitz SA;Foulkes AS;Ho JE
通讯作者：
Ho JE
影响因子：
5.8
作者：
Chiang JY
通讯作者：
Chiang JY
影响因子：
9
作者：
Danlos FX;Grajeda-Iglesias C;Durand S;Sauvat A;Roumier M;Cantin D;Colomba E;Rohmer J;Pommeret F;Baciarello G;Willekens C;Vasse M;Griscelli F;Fahrner JE;Goubet AG;Dubuisson A;Derosa L;Nirmalathasan N;Bredel D;Mouraud S;Pradon C;Stoclin A;Rozenberg F;Duchemin J;Jourdi G;Ellouze S;Levavasseur F;Albigès L;Soria JC;Barlesi F;Solary E;André F;Pène F;Ackerman F;Mouthon L;Zitvogel L;Marabelle A;Michot JM;Fontenay M;Kroemer G
通讯作者：
Kroemer G
影响因子：
16.6
作者：
Giovannoni F;Li Z;Remes-Lenicov F;Dávola ME;Elizalde M;Paletta A;Ashkar AA;Mossman KL;Dugour AV;Figueroa JM;Barquero AA;Ceballos A;Garcia CC;Quintana FJ
通讯作者：
Quintana FJ